Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: Translating clinical trial experience into clinical practice

Reviews in Cardiovascular Medicine

Volumn 15, Issue 1, 2014, Pages 1-10

  Toth, Peter P ^a,b   Shah, Prediman K ^c   Wilkinson, Michael J ^d   Davidson, Michael H ^d   McCullough, Peter A ^e,f  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e St John Providence Health System   (United States)

^f PROVIDENCE HOSPITAL   (United States)

Author keywords

Atherosclerosis; Homozygous familial hypercholesterolemia; Lomitapide; Low density lipoprotein cholesterol; Microsomal triglyceride transfer protein; Very low density lipoprotein cholesterol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; BILE ACID; CHOLESTEROL; CYTOCHROME P450 3A4; ESSENTIAL FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERMEDIATE DENSITY LIPOPROTEIN; LIPID TRANSFER PROTEIN; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; BENZIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; CARRIER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR, HUMAN;

ABETALIPOPROTEINEMIA; APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; ENDOPLASMIC RETICULUM; FAMILIAL HYPERCHOLESTEROLEMIA; FAT CONTENT; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID APHERESIS; LIVER DISEASE; LOSS OF FUNCTION MUTATION; LOW FAT DIET; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; UPREGULATION; BLOOD; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; HOMOZYGOTE; LIVER; METABOLISM; MUTATION; REVIEW; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; BIOLOGICAL MARKERS; CARRIER PROTEINS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIVER; MUTATION; RECEPTORS, LDL; TREATMENT OUTCOME;

EID: 84901915845     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0702     Document Type: Article

References (38)

1. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262-268.
2. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
3. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-156. (Pubitemid 46089675)
4. Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in ApoB-lipoprotein assembly. J Lipid Res. 2003;44:22-32. (Pubitemid 36114766)
5. Jamil H, Dickson JK Jr, Chu CH, et al. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J Biol Chem. 1995;270:6549-6554.
6. Atzel A, Wetterau JR. Mechanism of microsomal triglyceride transfer protein catalyzed lipid transport. Biochemistry. 1993;32:10444-10450. (Pubitemid 23320169)
7. Cuchel M, Rader DJ. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol. 2013;24:246-250.
8. Wetterau JR, Combs KA, Spinner SN, Joiner BJ. Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex. J Biol Chem. 1990;265:9800-9807.
9. Lamberg A, Jauhiainen M, Metso J, et al. The role of protein disulphide isomerase in the microsomal triacylglycerol transfer protein does not reside in its isomerase activity. Biochem J. 1996;315:533-536. (Pubitemid 26129503)
10. Wetterau JR, Combs KA, McLean LR, et al. Protein disulfide isomerase appears necessary to maintain the catalytically active structure of the microsomal triglyceride transfer protein. Biochemistry. 1991;30:9728-9735.
11. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999-1001.
12. Pons V, Rolland C, Nauze M, et al. A severe form of abetalipoproteinemia caused by new splicing mutations of microsomal triglyceride transfer protein (MTTP). Hum Mutat. 2011;32:751-759.
13. Ohashi K, Ishibashi S, Osuga J, et al. Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J Lipid Res. 2000;41:1199-1204. (Pubitemid 30666884)
14. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136-150. (Pubitemid 27138415)
15. Wu X, Zhou M, Huang LS, et al. Demonstration of a physical interaction between microsomal triglyceride transfer protein and apolipoprotein b during the assembly of ApoB-containing lipoproteins. J Biol Chem. 1996;271:10277-10281. (Pubitemid 26132519)
16. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: An MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003;44:1887-1901. (Pubitemid 37356661)
17. Bakillah A, Hussain MM. Binding of microsomal triglyceride transfer protein to lipids results in increased affinity for apolipoprotein B: evidence for stable microsomal MTP-lipid complexes. J Biol Chem. 2001;276:31466-31473. (Pubitemid 37385020)
18. Liao W, Hui TY, Young SG, Davis RA. Blocking microsomal triglyceride transfer protein interferes with ApoB secretion without causing retention or stress in the ER. J Lipid Res. 2003;44:978-985. (Pubitemid 37279657)
19. Jamil H, Gordon DA, Eustice DC, et al. An inhibitor of the microsomal triglyceride transfer protein inhibits ApoB secretion from Hep G2 cells. Proc Natl Acad Sci U S A. 1996;93:11991-11995. (Pubitemid 26347236)
20. Wetterau JR, Gregg RE, Harrity TW, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 1998;282:751-754. (Pubitemid 28489389)
21. Ueshima K, Akihisa-Umeno H, Nagayoshi A, et al. Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Westerntype diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull. 2005;28:247-252. (Pubitemid 40880003)
22. Goldberg AC, Hopkins PN, Toth PP, et al National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 suppl):S1-S8.
23. Wierzbicki AS, Humphries SE, Minhas R; Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ. 2008;337:a1095.
24. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111:1795-1803. (Pubitemid 38057721)
25. Juxtapid [package insert]. Cambridge, MA: Aegerion Pharmaceuticals; 2013.
26. Cuchel M, Meagher EM, du Toit Theron H, et al; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40-46.
27. Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013;13:285-296.
28. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-587. (Pubitemid 28182422)
29. Marais AD, Raal FJ, Stein EA, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008;197:400-406. (Pubitemid 351284477)
30. Raal FJ, Pappu AS, Illingworth DR, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000;150:421-428. (Pubitemid 30336555)
31. Gagné C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-2475. (Pubitemid 34568966)
32. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-414. (Pubitemid 43228152)
33. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761-1770. (Pubitemid 47494553)
34. SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 2008;359:789-799.
35. Eckel RH. Approach to the patient who is intolerant of statin therapy. J Clin Endocrinol Metab. 2010;95:2015-2022.
36. Robinson JG. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Manag Care Pharm. 2013;19:139-149.
37. Goldberg AC. Emerging low-density lipoprotein therapies: microsomal triglyceride transfer protein inhibitors. J Clin Lipidol. 2013;7(3 suppl):S16-S20.
38. Cuchel M, Meagher EM, du Toit Theron H, et al. Apheresis treatment does not affect the lipid-lowering efficacy of lomitapide, a microsomal triglyceride transfer protein inhibitor, in patients with homozygous familial hypercholesterolemia. Circulation. 2012;126:A17396.